Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Livagen

Livagen (Lys-Glu-Asp-Ala / KEDA), Khavinson liver bioregulator tetrapeptide

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

Livagen's supported activity rests on in vitro human lymphocyte chromatin studies from a single Russian group (Khavinson, Lezhava, Monaselidze; Bull Exp Biol Med 2002, PMID 12533768), which report decondensation of pericentromeric heterochromatin and reactivation of ribosomal genes in cultured cells from elderly donors. There are no human randomized controlled trials, no replication by independent Western laboratories, and the proposed direct peptide-DNA binding mechanism (Fedoreyeva, Vanyushin, Khavinson) remains unconfirmed outside the originating group, so the evidence is preliminary and animal/in-vitro tier only.

FDA
No FDA approval; sold as a research chemical labeled not for human consumption, with no completed FDA action on record
WADA
Not listed on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

No human clinical trials; unreplicated single-group Russian in vitro data; sold as an unregulated research chemical with unverified purity and no human safety profile

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Livagen. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A Khavinson liver peptide bioregulator. Proposed mechanism: epigenetic gene regulation in liver tissue.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Liver function optimization
  • Longevity protocol

How it is supposed to work

Livagen is a synthetic peptide (lysine, glutamic acid, aspartic acid, alanine) directed at the liver, promoted to support hepatic function and, in the bioregulator model, to influence liver-tissue gene activity. The mechanism is unproven in rigorous human studies.

Livagen is a synthetic short peptide, a defined-sequence second-generation bioregulator aimed at liver tissue, part of the same organ-by-organ lineup as the pancreas peptide Pancragen and the heart peptide Cardiogen.

Type
Synthetic short peptide
Target
Liver
Generation
Second (defined)
Use
Pulsed courses
Evidence
Preclinical and Russian
Western RCT
None

The Liver Label On A Single-Lineage Peptide System

Livagen carries the family’s signature claim and the family’s evidence problem without variation. The proposed action is direct peptide-driven gene regulation in liver tissue, a mechanism not established outside the originating group, and the hepatic-support claims are preclinical and Russian with no independent human trials. It is one more tissue-labeled member of a system whose entire evidence base comes from one research lineage, and the liver framing adds a particular caution, since real liver disease has proper diagnosis and treatment that an unproven peptide should never displace.

Safety in detail

Human safety data are absent. The available research is limited to in vitro human-cell and preclinical models from the originating laboratory, so any parenteral human use is off-label and unstudied, with product identity and sterility resting entirely on vendor claims.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Livagen has no validated pediatric use and is an unapproved injected peptide. There is no appropriate pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Livagen reaches users only through the bioregulator gray market and longevity vendors selling the Khavinson line, with no approved product.

How we got here

Livagen is one of the synthetic short-peptide bioregulators created by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the late 1990s and early 2000s. It belongs to the 'cytogen' generation of Khavinson peptides, synthetic sequences designed to reproduce the organ-specific activity of the earlier 'cytomedin' tissue extracts, with the name derived from the liver as its intended target organ. Its documented evidence begins with the 2002 Bulletin of Experimental Biology and Medicine chromatin study and later mechanistic work by Fedoreyeva and Vanyushin on peptide-DNA binding, all from the originating Russian group. Outside Russia it has no approved medicinal product and circulates only as a research chemical sold online, frequently alongside its close relative Vilon (the tripeptide Lys-Glu-Asp / KED), with which it is often confused.

Livagen was developed as a defined-sequence organ bioregulator at the St. Petersburg institute, extending Khavinson’s tissue-by-tissue approach to the liver.

The numbers behind the grade

Type
Peptide (Lys-Glu-Asp-Ala)
Target
Liver
Russia
Bioregulator line
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

A liver-targeted bioregulator with a small following in longevity circles.

Livagen’s users are longevity and detox-focused enthusiasts and the bioregulator-protocol community.

Used as a liver-support bioregulator within Russian-tradition protocols; evidence is limited and not independently confirmed.

Set against the alternatives

Livagen is the hepatic counterpart to the pancreas peptide Pancragen and the vascular peptide Vesugen, sharing Epithalon’s longevity framing applied to the liver. Its support is preclinical and single-lineage, in contrast to evidence-based hepatology.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Livagen.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group studies2000s

    Reported hepatic and chromatin-related effects in the bioregulator literature.

  • Independent replicationnone notable

    No independent Western trials of Livagen exist.